ArriVent BioPharma's second quarter was the moment the calendar said everything was supposed to work: a global pivotal Phase 3 readout for the lead drug, firmonertinib, is now within months, a second antibody-drug conjugate advanced into dose optimization, and a third program dosed its first patient. Inside the quarter, R&D rose 53% to $42.3M, the net loss widened to $(49.9)M from $(31.4)M a year ago, and the cash position grew to $373.1M after a $140M financing - funded through at least 2028 by management's count. None of that changed the multiple, which compressed rather than expanded. The stock gave back a meaningful portion of its June peak, and not because the quarter disappointed on its own line items; because the competitive picture in EGFR exon 20 insertion non-small cell lung cancer hardened in July when AstraZeneca took global rights to a competing pill. The next six months are about the readout, not the income statement.
The shape of the quarter, looked at cleanly: operating expenses jumped to $52.7M from $33.6M, almost entirely on a $9.8M acceleration in early-stage ADC work and a $3.4M increase in personnel as the pipeline broadened; net loss per share was $(1.05) on 47.6M weighted shares versus $(0.90) on 35.0M. The $5.0M of incremental Phase 3 spend ran into the same quarter that investors began to price in a world with a second approved exon 20 pill. The cash story is the one piece of the quarter that unambiguously improved - $373.1M of cash and short-term investments at quarter-end, up from $312.8M at year-end 2025, after a public offering of common stock and pre-funded warrants that netted $140M. The open question is whether the data the company is on the verge of releasing can dislodge a market that is increasingly treating firmonertinib as a second-mover, not the first. The single number the rest of the year pivots on is the firmonertinib global pivotal Phase 3 (FURVENT) topline readout in the second half of 2026. If the data confirm the earlier 79% response-rate signal, the equity rerates; if they underwhelm, the cash buys time but not a thesis.